Nephrology and Hypertension

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. A Cross-sectional Study Examining Adipose Tissue in Obstructive Sleep Apnea

   Rochester, Minn.

   Studies show that sleep apnea increases the risk of cardiovascular disease and is associated with obesity. However, it is unclear how sleep apnea affects fat tissue. Studies have shown that fat tissue is likely involved in developing cardiovascular disease. The purpose of this study is to see how sleep apnea changes fat tissue.

2. REstrictive versus LIberal Rate of Extracorporeal Volume Removal Evaluation in Acute Kidney Injury (RELIEVE-AKI)

   Rochester, Minn.

   The objective of this study is to evaluate the feasibility of alternative Net Ultrafiltration (UFNET) rate strategies among critically ill adults with acute kidney injury (AKI) and treated with Continuous Kidney Replacement Therapy (CKRT).

    

3. Evaluation of the Total Kidney Volume AI Algorithm

   Rochester, Minn.

   The natural course of autosomal dominant polycystic kidney disease (ADPKD) is highly variable and typically characterized by progressive enlargement of cysts within the kidneys.  ADPKD is a leading cause of end-stage renal disease.  Recently, a new medication called Tolvaptan has been approved by the FDA to slow progression of ADPKD.  Accurate, MR based kidney volume measurements are the best parameter for following the progression of ADPKD, and are suggested be acquired to measure progression and effects of Tolvaptan.  However, making these slice-by-slice volume measurements can be extremely time consuming when done manually.  The purpose of this work is to evaluate an AI algorithm to make the measurements.  The results of the algorithm will be reviewed by a qualified radiologist familiar with the algorithm’s results.  If the radiologist agrees with the results, kidney volumes (left, right and combined) will be recorded for clinical use.  The usage of the algorithm in this setting (with review by radiologist, and manual correction) is a minimal risk to the patients: a failure of the algorithm will have no impact on treatment and errors will be caught and corrected by the QC process. Because the algorithm will not be used solely for diagnosis or inform treatment without the confirmation of the diagnosis by another, medically established diagnostic product or procedure this study constitutes minimal risk to patients. 

4. Study to Evaluate Clinical Complications, Pattern of Kidney Function Decline and Identification of Clinical Variables Related to Progression of Autosomal Dominant Polycystic Kidney Disease

   Rochester, Minn.

   The purpose of this study is to evaluate clinical complications, pattern of kidney function decline and identification of clinical variables related to progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

5. Evaluating Kidney Stones To Determine If They Lead to Kidney Disease

   Rochester, Minn.

   We hypothesize that clinical studies to investigate the role of individual proteins in kidney stone pathogenesis have likely been confounded by an unknown variety of underlying renal pathologies. Therefore, we propose to examine urinary protein crystallization inhibitors in patient populations that have been carefully phenotyped relative to renal stone precursor lesions by direct endoscopic visualization. In collaboration with Project #1, our second major goal is to use these accurately phenotyped patients in order to adapt modern dual-energy CT technology to develop a reliable noninvasive technique to accurately and noninvasively determine stone composition and visualize the earliest kidney stone precursor lesions. Our long-term goal is to improve CT technology so that it can be used to allow large-scale clinical protocols of accurately phenotyped, hence, homogeneous, patient populations.
   
   In a subset we will sample sterile stone, dental plaque, blood and urine samples for detailed microbiome analysis in order to determine the contribution of micro organisms to stone pathogensis.

6. Monogenic Kidney Stone - Genetic Testing

   Rochester, Minn.

   90 genes related to Monogenic Stone Disease will be determined via DNA analysis by the Mayo Rare Kidney Stone Consortium (RKSC) research staff.

7. A Study to Predict Sepsis-Associated Acute Kidney Injury by Assessing Renal Microvascular Blood Flow and Elasticity with Contrast-Enhanced Ultrasonography and Ultrasound Elastogram

   Rochester, Minn.

   The purpose of this study is to assess kidney microcirculation using contrast-enhanced ultrasonography associated with kidney ultrasound elastography among patients who are at risk of sepsis-associated acute kidney injury provides strong predictive ability for AKI and potential therapeutic targets. 

    

8. A Study to Evaluate the Effectiveness and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

   Rochester, Minn.

   The purpose of this study is to investigate how efficiently the study medication imlifidase reduces the amount of donor specific antibodies (DSA) in comparison with plasma exchange (PE) therapy, in patients who have an active antibody mediated rejection (AMR) after recently been kidney transplanted. The purpose is also to investigate and compare safety for these two treatments. 20 patients will be treated with imlifidase and 10 with PE.